Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186641 | 0.85 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL127441 | 0.82 | — | — | |
| SCHEMBL666377 | 0.80 | — | — | |
| SCHEMBL11470901 | 0.78 | NPC1 (0.45) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL3762069 | 0.77 | — | — | |
| SCHEMBL130811 | 0.77 | — | — | |
| SCHEMBL25155794 | 0.76 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL22151418 | 0.76 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL11471966 | 0.76 | NPC1 (0.43) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL2384777 | 0.76 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833824-B1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| CN-1863794-B | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2012-04-25 | — | — | CN | disclosed |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-20110065685-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-7750039-B2 | Indoles are cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
| EP-1313726-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1311500-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016348-A1 | ANTIANGIOGENIC BICYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | SLC6A2 375/4885SLC6A4 450/4885SLC6A3 428/4885 |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | SLC6A2 627/4885SLC6A4 791/4885SLC6A3 743/4885 |
| US-20110065685-A1 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS | CNR2, CNR1, OPRL1 | SLC6A2 732/4885SLC6A4 383/4885SLC6A3 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.